Bridgewater Associates LP Sells 38,671 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridgewater Associates LP trimmed its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 35.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 70,462 shares of the medical equipment provider’s stock after selling 38,671 shares during the period. Bridgewater Associates LP owned 0.10% of Lantheus worth $7,733,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farallon Capital Management LLC increased its position in Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after buying an additional 796,000 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Swedbank AB raised its stake in shares of Lantheus by 21.1% in the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock valued at $79,266,000 after acquiring an additional 125,843 shares in the last quarter. Boston Partners lifted its holdings in Lantheus by 21.2% in the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock worth $42,696,000 after purchasing an additional 119,156 shares during the last quarter. Finally, LSV Asset Management boosted its position in Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock worth $51,462,000 after purchasing an additional 139,647 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.8 %

Shares of LNTH opened at $90.27 on Friday. The stock’s 50-day moving average price is $102.12 and its 200 day moving average price is $97.09. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The firm has a market capitalization of $6.28 billion, a price-to-earnings ratio of 15.02 and a beta of 0.51.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. JMP Securities dropped their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.